The sequential use of abiraterone and enzalutamide (MDV3100) in castrate resistant prostate cancer patients: Experience from Birmingham, United Kingdom.

被引：0
|
作者：
Stevenson, Robert
Ford, Daniel
Zarkar, Anjali M.
Glaholm, John
Porfiri, Emilio
Tew, Alice
El-Modir, Ahmed
James, Nicholas David
机构：
[1] Univ Hosp Birmingham, Birmingham, W Midlands, England
[2] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England
[3] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England
[4] Univ Birmingham, Sch Canc Sci, Birmingham, W Midlands, England
[5] Univ Birmingham, Birmingham, W Midlands, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16048
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.
    Buonerba, Carlo
    Sonpavde, Guru
    Pond, Gregory Russell
    Pagliuca, Martina
    Rossetti, Sabrina
    Facchini, Gaetano
    Scagliarini, Sarah
    Daniele, Bruno
    Federico, Piera
    Morelli, Franco
    Carteni, Giacomo
    Ferro, Matteo
    Lucarelli, Giuseppe
    Bellelli, Teresa
    De Placido, Sabino
    di Lorenzo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] A retrospective study on cabazitaxel and abiraterone acetate sequential treatment (CAST) in docetaxel treated metastatic castrate-resistant prostate cancer patients
    Wissing, M. D.
    Coenen, J. L. L. M.
    Van den Berg, P.
    Van Oort, I. M.
    De Wit, R.
    Bergman, A. M.
    Westgeest, H. M.
    Hamberg, P.
    Los, M.
    Gelderblom, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S698 - S698
  • [33] MDV3100, an Androgen Receptor Signaling Inhibitor, Improves Overall Survival in Patients with Prostate Cancer Post Docetaxel: Results from the Phase 3 AFFIRM Study
    Mulders, P.
    Scher, H.
    Fizazi, K.
    Saad, F.
    Taplin, M.
    Sternberg, C.
    Miller, K.
    De Wit, R.
    Hirmand, M.
    Selby, B.
    De Bono, J.
    UROLOGY, 2012, 80 (03) : S30 - S30
  • [34] Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study
    Scher, Howard I.
    Fizazi, Karim
    Saad, Fred
    Taplin, Mary-Ellen
    Sternberg, Cora N.
    Miller, Kurt
    De Wit, Ronald
    Mulders, Peter
    Hirmand, Mohammad
    Selby, Bryan
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [35] Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience
    Raju, R.
    Sahu, A.
    Klevansky, M.
    Torres, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1332 - S1332
  • [36] Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC)
    Efstathiou, E.
    Tu, S.
    Aparicio, A.
    Hoang, A.
    Wen, S.
    Troncoso, P.
    Smith, L. A.
    Chieffo, N.
    Molina, A.
    Logothetis, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Impact of prior therapy with ketoconazol or abiraterone and pattern of PSA response in a cohort of patients with metastatic castrate resistant prostate cancer (mCRPC) receiving enzalutamide for postdocetaxel.
    Maroto Rey, Jose Pablo
    Esteban, Emilio
    De Liano Lista, Alfonso Gomez
    Ruiz Echevarria, Ana
    Virgill, Ana
    Moreno, Estela
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel
    Wissing, Michel D.
    Coenen, Jules L. L. M.
    van den Berg, Pieter
    Westgeest, Hans M.
    van den Eertwegh, Alfons J. M.
    van Oort, Inge M.
    Bos, Monique M.
    Bergman, Andre M.
    Hamberg, Paul
    ten Tije, Albert J.
    Los, Maartje
    Lolkema, Martijn P. J. K.
    de Wit, Ronald
    Gelderblom, Hans
    INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (06) : E760 - E772
  • [39] Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
    Fong, Peter C. C.
    Retz, Margitta
    Drakaki, Alexandra
    Massard, Christophe
    Berry, William R.
    Romano, Emanuela
    De Bono, Johann S.
    Feyerabend, Susan
    Appleman, Leonard Joseph
    Conter, Henry Jacob
    Sridhar, Srikala S.
    Shore, Neal D.
    Linch, Mark David
    Joshua, Anthony
    Gurney, Howard
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [40] Comparison of outcomes for patients with metastatic castrate resistant prostate cancer treated by urologists or medical oncologists with first line abiraterone acetate or enzalutamide: a population-based study
    Woon, D.
    Finelli, A.
    Wallis, C. J. D.
    Cheung, D.
    Martin, L.
    Saskin, R.
    Fleshner, N.
    BJU INTERNATIONAL, 2020, 125 : 56 - 57
12345